Dasatinib-Induced Chylothorax: A Clinical Laboratory's Perspective

Dasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely reported as a secondary effect of dasatinib occurring especially in long-term treated patients, although its pathophysiology is not yet fully understood. Laboratory analysis...

Full description

Saved in:
Bibliographic Details
Published in:EJIFCC 2023-04, Vol.34 (1), p.76-80
Main Authors: Martínez, Rafael J García, Gea, Clara Sanz, Martin-Riera, Víctor, Ruiz, Armando Raúl Guerra, Barzanti, Rosanna Paciucci, Ferrer-Costa, Roser, Ramirez-Serra, Clara
Format: Article
Language:English
Subjects:
Case Report
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely reported as a secondary effect of dasatinib occurring especially in long-term treated patients, although its pathophysiology is not yet fully understood. Laboratory analysis of the pleural effusion is crucial for chylothorax diagnosis. We report a case of a 53-year-old male patient presenting a chylothorax after 14 years of dasatinib therapy where the clinical laboratory was key in the diagnosis.
ISSN:1650-3414